Related Experiment Videos
Time trends in warfarin-associated hemorrhage
Nils Kucher1, Luis R Castellanos, Rene Quiroz
1Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
The American Journal of Cardiology
|July 28, 2004
Summary
Warfarin-related bleeding events, including major and intracranial hemorrhages, saw an increase in incidence and proportion over the study period. This highlights a growing concern for patient safety during warfarin therapy.
Area of Science:
- Medical research
- Clinical outcomes
- Patient safety
Background:
- Warfarin is a widely prescribed anticoagulant.
- Bleeding is a significant risk associated with warfarin therapy.
- Monitoring warfarin-related bleeding is crucial for patient care.
Purpose of the Study:
- To analyze trends in warfarin-related bleeding incidence.
- To assess changes in the proportion of major and intracranial bleeding events.
- To evaluate patient safety outcomes related to warfarin use over time.
Main Methods:
- Retrospective analysis of patient data.
- Comparison of bleeding event rates between two distinct time periods.
- Calculation of annual incidence and proportion of bleeding types.
Main Results:
- Annual incidence of warfarin-related bleeding increased from 0.97 to 1.19 per 1,000 patient admissions.
- Proportion of major bleeding events rose from 20.2% to 33.3%.
- Proportion of intracranial bleeding events increased from 1.9% to 7.8%.
Conclusions:
- There was a notable increase in warfarin-associated bleeding events.
- The severity of bleeding events, particularly major and intracranial, also increased.
- Findings underscore the need for vigilant monitoring and management of warfarin therapy.